Aroa Biosurgery Limited (ASX: ARX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Aroa Biosurgery Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Aroa Biosurgery Limited (ASX: ARX)
Latest News
Healthcare Shares
These were the best performing ASX healthcare shares in October
Share Gainers
Aroa Biosurgery (ASX:ARX) share price up 14% on strong half
Share Market News
Capital keeps flowing into ASX Biotech shares in 2021
Healthcare Shares
3 ASX healthcare shares with big news coming
Share Gainers
Aroa Biosurgery (ASX:ARX) share price rises on results and strong guidance
Share Market News
Why the Aroa Biosurgery (ASX:ARX) share price is lifting today
Healthcare Shares
How do Avita Medical (ASX:AVH) shares stack up against Polynovo and Aroa Biosurgery?
Healthcare Shares
The Aroa (ASX:ARX) share price has surged 60% since its IPO
Share Market News
Brace for an IPO resurgence as new floats beat the ASX 200 by ~50%
Share Fallers
Why Aroa Biosurgery, Straker, Virgin Money, & Whitehaven shares are dropping lower
⏸️ ASX Shares
Leading fund managers name 4 small cap ASX shares to buy
Share Market News
Aroa Biosurgery share price jumps 8% on approvals
Frequently Asked Questions
-
No, Aroa Biosurgery does not pay shareholder dividends at this time.
-
Aroa Biosurgery Ltd listed on the ASX on 24 July 2020.
ARX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Aroa Biosurgery Limited
Aroa Biosurgery Ltd (ASX: ARX) is a New Zealand-based biomedical company specialising in soft tissue regeneration. It develops, manufactures, and distributes medical and surgical products to improve the healing of complex wounds and soft tissue reconstruction.
The company's principal market is the United States where it markets four key products targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
Its first wound-healing product Endoform was approved by the US Food & Drug Administration (FDA) in 2013. Aroa's first commercial surgical product, a reinforced bioscaffold developed in collaboration with US company Tela Bio Inc., was approved by the FDA in 2014.